NKCx Histopathological outcome* within 12 months after cervix cytology in 2024
651 Norrbotten

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 26 5.7% 13 2.8% 14 3.1% . . . . . . 404 88.4% 457 100.0%
ASCUS 40 35.1% 28 24.6% 25 21.9% . . . . 1 0.9% 20 17.5% 114 100.0%
LSIL 25 26.6% 31 33.0% 26 27.7% . . . . 1 1.1% 11 11.7% 94 100.0%
Atypical glandular cells/AGC . . 1 50.0% . . 1 50.0% . . . . . . 2 100.0%
Unclear atypia . . . . 1 100.0% . . . . . . . . 1 100.0%
ASC-H 2 11.1% 3 16.7% 9 50.0% 1 5.6% 1 5.6% . . 2 11.1% 18 100.0%
HSIL 3 17.6% 1 5.9% 10 58.8% . . 1 5.9% . . 2 11.8% 17 100.0%
Squamous cell cancer . . . . 2 66.7% . . 1 33.3% . . . . 3 100.0%
Totalt 96 13.6% 77 10.9% 87 12.3% 2 0.3% 3 0.4% 2 0.3% 439 62.2% 706 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes
in the category
Cancer:
M80703